Drug class
Folate receptor alpha (FRα)-directed antibody–drug conjugate; microtubule inhibitor payload
Mechanism of action
The antibody binds FRα on tumour cells and is internalised. Intracellular cleavage releases DM4, a maytansinoid microtubule inhibitor that disrupts the microtubule network, causing cell-cycle arrest and apoptotic cell death.
General use cases
- Treatment of adults with FRα-positive, platinum-resistant epithelial ovarian, fallopian-tube or primary peritoneal cancer after one to three prior systemic treatment regimens, using an FDA-authorised FRα test; see current label for eligibility and ocular monitoring
For general informational purposes only. Do not rely on, cross-reference, cite or use this information as evidence or support for legal, regulatory, commercial or other claims.
